Kornimate/medical-research-clean huggingface dataset:
image quality and radiation dose associated with cardiac scans in modern ct scanners

Conditions: Coronary Artery Disease

Summary: the main objective of this study is to evaluate the dose efficiency of coronary ct angiography (cta) using a photon counting detector ct (pcd-ct) with the dose efficiency of coronary ct angiography of prior ct generations. 100 patients with a clinical indication for coronary ct angiography will be prospectively enrolled and undergo coronary cta on a pcd-ct. for comparison, a matched retrospective cohort of 100 patients will be created who had undergone on a prior scanner generation (retrospective cohort).


Eligibility criteria:
inclusion criteria: * indication for coronary cta confirmed by board-certified radiologist ('justified indication' according to german/european radiation protection law) and * patient (is able to give informed consent and) has given informed consent. exclusion criteria: * contraindications to (iodine based) iv contrast material: known allergy to iodine-based iv contrast, acute or high-grade chronic kidney insufficiency with an estimated glomerular filtration rate \< 30 ml/min/1.73 m², latent or manifest hyperthyroidism * known or suspected pregnancy * lactating mothers

Keywords: spectral ct multi-energy ct photon counting detector ct pcd-ct
cognition and affect after stroke: a prospective evaluation of risks

Conditions: Vascular Cognitive Impairment; Post-stroke Depression; Post-stroke Apathy; Post-stroke Dementia; Vascular Dementia

Summary: stroke is a leading cause of disability, affecting about 34,000 to 41,000 individuals in the netherlands of middle and old age every year. due to the aging of the population, this figure will increase considerably over the next decades (struijs et al., 2005). twenty-five percent of stroke patients die within one month, making stroke a major risk factor for premature death in developed countries. according to the world health organization, stroke is the third leading cause of the burden of disease in middle and high-income countries (world health organization, 2008). it has a significant negative impact on quality of life of both the patients as well as their caregivers and significant others. surviving stroke patients often struggle with its manifold and lifelong lasting consequences, with 35 percent of patients being functionally dependent one year after stroke (wolfe, 2000) and cognitive and emotional changes which are found up to two years post-stroke (rasquin, lodder, \& verhey, 2005). depression, apathy, and cognitive impairment are very prevalent and significantly contribute to the burden of the disease, but their etiologies remain poorly understood. the aim of the casper study is to gain more insight into the etiologies of post-stroke depression (psd), post-stroke apathy (psa), vascular cognitive impairment (vci), and post-stroke dementia. therefore, the primary objectives are to identify biomarker-based predictors of psd, psa, and vci. a secondary aim is to study effect modulation, especially the interaction between cerebrovascular disease, neurodegenerative changes and inflammation in post-stroke dementia. casper is a prospective clinical cohort study of 250 first-ever ischemic stroke patients with serial assessments at baseline (10 to 12 weeks after stroke), six and 12 months after baseline. another wave (36 month after baseline) was later added.


Eligibility criteria:
inclusion criteria: * first-ever or recurrent ischemic or hemorrhagic stroke * mmse score ≥15 (to ensure valid testing) * written informed consent * sufficient knowledge of the dutch language * preferably participation of an informant exclusion criteria: * age younger than 40 years (to exclude atypical strokes) * pre-stroke dementia (assessed by a semi-structured interview with a relative, based on clinical diagnosis or iq-code) in the five years prior to stroke * psychiatric and neurological disease other than the qualifying event known to affect cognition such as schizophrenia, bipolar disorder, substance abuse, parkinson's disease, or epilepsy * current episode of depression at admission (as evidenced by medical records and patient or informant interview). in contrast, a lifetime history of depression will not be considered as a reason for exclusion as this is considered a potential risk factor for psd * severe aphasia (as it interferes with understanding and following test instructions)
incretin and crtd.

Conditions: Type 2 Diabetes Mellitus; Heart Failure

Summary: incretin therapy is a treatment for type 2 diabetes (t2dm) affected by heart failure (hf). in this study the investigators will recruit t2dm patients affected by hf with depressed ejection fraction and treated by cardiac resynchronization therapy (crt). these patients will randomly be treated by incretin v/s conventional hypoglicemic drugs. in this patients investigators will report at follow up crt-d responders rate, mortality, and hospital admission for hf worsening. incretin may reduce hospital admissions for hf in t2dm v/s conventional hypoglicemic drugs.


Eligibility criteria:
inclusion criteria: * aged more than 18 years, with clinical hystory of t2dm non insulin dependent, and diagnosed failing heart with depressed ejection fraction; crtd recipients. exclusion criteria: * t2dm in insuline therapy; renal impairment, chronic inflammatory and systemic diseases; neoplastic diseases.
the correlation between the enzyme paraoxigenase 1 (pon1) to carotid artery atheromatous plaque

Conditions: Carotid Artery Stenosis

Summary: the objective of the research, is to examine the hypothesis, that the enzyme paraoxygenase 1 ( pon1) can influence carotid artery's atherosclerotic plaque content and stability, and its relation to plasma's enzyme concentration.

atherosclerosis is a major risk factor for morbidity and mortality in the western world. it is characterized by the accumulation of fat (cholesterol) in the arterial wall, creation of the atheromatous plagues and the creation of arterial stenosis and occlusion. the cellular content of theses plaques include: fibroblasts, endothelial cells, smooth muscle cells, macrophages, and lipids: phospholipids, cholesterol, oxysterols and fatty acids. lipids penetration from the blood stream collaborates different proteins, including the anti-atherogenic enzyme - paraoxygenase 1 - pon1. this enzyme has many ani-atherogenic activities, e.g. protection from oxygenation and increase of cholesterol efflux from macrophages by hdl. although the enzyme has a verity of substrates and known anti-atherogenous function, its mechanism is still vogue. the enzymes accumulation rate is the function of the advancement of the fatty strike towards advanced lesion. there is evidence that the presence accumulation and activity of the pon1 within the plaque, is a defense mechanism against atherosclerosis development. the assumption to be proved is that pon1 can control plaque's content and influence its atherogenous factors. furthermore, we will try to identify these factors that the pon1 acts on. beside plaque's content and pon1's influence on them, we would like to investigate the phenotype of haptoglobin in the subjects that the plaques were removed from. it is known that diabetics that have the genotype haptoglobin 2-2, characterized by increased risk for oxygenation stress and cardiovascular events (up to 5 times). we would like to examine if there is a correlation between plaque's content, pon1's ability to disassemble oxygenized factors within the plaque, and the phenotype to haptoglobin. methods: the plaque source will be from carotid endarterectomy, in the vascular unit. this procedure is a routine operation for patients suffering from carotid artery stenosis, based on clinical decisions. the plaques will be transported to a lipid laboratory soon after they will be harvested, will be frozen in liquid nitrogen and processed into powder. this material will be the origin for the proteins we try to extract. patient's blood samples (that is drawn routinely for the operation) will be the source for the characterization of the haptoglobin's genotype. it is critical to emphasize that routinely, the plaques are waste products, and only 5 cc of additional blood is withdrawn from the patients for research purposes.

Eligibility criteria:
inclusion criteria: * patients undergoing cea

Keywords: carotid artery atherosclerotic plaque paraoxygenase 1 pon1 patients undergoing carotid artery endarterectomy cea for carotid artery stenosis
telerehabilitation as follow-up for obesity

Conditions: Obese Patients

Summary: the goal of this experimental study is to observed the impact of telerehabilitation modalities in obese patient after a hospitalization on physical intensity at home (mvpa). the secondary aim is to observe the evolution of clinical parameters such as anthropometric data, adherence and psychological state.


Eligibility criteria:
inclusion criteria: * adult (\> 18 years old) * bmi \> 35 or 30 kg/m2 in case of concomitant comorbidity * authorization to practice physical activity for participants over 30 years old by means of a cardiac assessment and an ecg less than 6 months old carried out by a cardiologist. as part of the cobd treatment, the ecg is either: integrated into the patient file before hospitalization if the patient has seen his cardiologist staff. either the ecg is provided in the file or carried out and analyzed by the center's cardiologist (dr rouffaud). the latter then authorizes or not the practice of pa. * complete 3-week stay in an obesity center * availability of equipment suitable for telerehabilitation at home * having given informed consent for participation in the study exclusion criteria: * medical contraindication to pa practice defined by a doctor * participation in a concomitant research protocol * for women of childbearing age, they will be informed that in the event of pregnancy occurring during participation in the research, they will not be able to continue the protocol and will withdraw from the research * refusal to participate in the research protocol * patient on weekday stay (\< 3 weeks) * psychiatric/psychological disorder limiting the expression of consent * persons under legal protection or unable to express their consent * inability to participate in any of the 18 telerehabilitation sessions

Keywords: telerehabilitation obesity adults physical exercise mindsets
lab to real world assessment of e-cigarette abuse liability and appeal

Conditions: Nicotine Dependence

Summary: the proposed research is a longitudinal human lab study to examine how measures of abuse liability and product appeal vary by e-cigarette device type, and how these lab assessments may predict subsequent e-cigarette and other tobacco use behavior at 1,3, and 6 months. an additional aim is to evaluate e-cigarette safety and tolerability among smokers by device type.

the proposed research is a longitudinal human lab study to involving 6 lab visits and 3 follow-up surveys at 1, 3, and 6 months after participants' last lab visit. investigators will enroll 30 smokers (≥10 cig/day) who have not used e-cigarettes in the past 30 days and have never used e-cigarettes "fairly regularly." after a telephone screening to confirm eligibility, participants will attend virginia commonwealth university's (vcu) clinical behavioral pharmacology laboratory for all lab visits. the specific aims are to: aim 1. examine how measures of abuse liability and product appeal vary by ecig device type (markten vs. e-go). aim 2. compare differences in abuse liability and product appeal between participants' usual brand of tobacco cigarette, markten, and e-go. aim 3. as an exploratory aim, examine the extent to which measures of abuse liability and product appeal as measured in the lab (including tppt) predict participants' real-world ecig use at the 1-, 3-, and 6-month follow-up surveys. aim 4. to monitor safety and tolerability the markten and e-go among smokers.

Eligibility criteria:
inclusion criteria: 1. be between 18-65 years of age; 2. reside in the richmond metro area; 3. be proficient in english; 4. be interested in trying e-cigarettes, assessed at the initial screening; 5. have no immediate plans (in the next 30 days) to quit smoking; 6. have an active email address (for online follow-up surveys); 7. report current cigarette use (≥10 cpd for ≥1 year). to biochemically confirm cigarette smoking status, eligible participants must have an exhaled carbon monoxide (co) of ≥15ppm at screening using a vitalograph co monitor. exclusion criteria: individuals fitting any of the following criteria will not be eligible to participate. 1. individuals who have used e-cigarettes in the past 30 days; 2. individuals who used e-cigarettes more than 5 times in their lives; 3. individuals with uncontrolled or unstable medical or psychiatric conditions; 4. individuals with current or recent (within 6 months) drug/alcohol abuse; 5. individuals who weigh less than 110 lbs; 6. individuals with conditions that would require medical attention during the course of the study (such as hypertension \[systolic bp over 140, diastolic bp over 90\] or elevated heart rate \[over 90 bpm\]); 7. women who are currently pregnant/breastfeeding or who have plans to become pregnant.
clinical evaluation of cellutite treatment

Conditions: Cellulite of Thighs

Summary: this prospective study is intended to evaluate the cellutite rfal handpiece combined with morpheus8 handpiece for the treatment of cellulite.

the study will evaluate the safety and efficacy of cellulite treatment using two hand pieces: * the cellutite - based on a minimally invasive, temperature-controlled radiofrequency-assisted lipolysis (rfal) technology. rf energy is applied using a handpiece with 2 electrodes: internal active electrode with spatula-shaped tip and external electrode. * the morpheus8 - designed to deliver rf energy to the skin surface in a fractional manner via an array of 24-electrode pins.

Eligibility criteria:
inclusion criteria: * female subjects aged 18-70 having mild/moderate grade cellulites. * the patients should understand the information provided about the treatment, possible benefits and side effects, and sign the informed consent form, (including the permission to use photography). * the patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods in the treatment area for the last 6 months and during the entire study period. exclusion criteria: * body fat layer thinner than 5mm. * pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. * superficial permanent implant in the treated area such as metal plates and screws, metal piercing, silicone implants or an injected chemical substance. * current or history of skin cancer (remission of 5 years), or current condition of any other type of cancer, or pre-malignant moles. * severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases. * pregnancy and nursing. * history of bleeding coagulopathies or use of anticoagulants. * impaired immune system due to immunosuppressive diseases such as aids and hiv or use of immunosuppressive medications. * poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization. * any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. * history of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. * use of isotretinoin (accutane®) within 6 months prior to treatment. * any surgery or treatment such as laser or chemicals in treated area within 3-6 months prior to treatment or before complete healing. * allergies, in particular to anesthesia. * mental disorders such as body dysmorphic disorder (bdd). * as per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient.
immune response of intradermal and intramuscular preparations of inactive seasonal influenza vaccine in older age group.

Conditions: Influenza, Human

Summary: this is a prospective, open label randomized study. a total of 220 adults aged ≥ 60 years will be enrolled and randomized to one of 2 study arms: 1. seasonal inactivated intradermal influenza vaccine (15 μg ha (hemagglutinin) per strain/ 0.1 ml dose) (group a - 110 participants) 2. seasonal inactivated intramuscular influenza vaccine (15 μg ha per strain/ 0.5 ml dose) (group b - 110 participants) groups a and b will receive the vaccine at day 1. total follow up period is 60 days.

the consent form will be reviewed and signed by the participant prior to any study-related procedures. potential study participants will be assessed based on inclusion and exclusion criteria. screening procedures, which include taking medical history, vital signs, random blood for dextrostix and vaccination will be performed on day 1. a total of 220 participants will be randomized into 2 study arms, of which each group of 110 vaccinees will receive either seasonal intradermal influenza vaccine \[group a\] or seasonal intramuscular influenza vaccine \[group b\]. the randomization route of vaccination will be kept in concealed envelope at the study site. it will be open after subject signed informed consent form and all inclusion exclusion criteria met for enrollment. groups a and b will receive the vaccine at day 1. clinical activities for groups a and b during each visit (total of 5 visits). blood will be drawn and assayed (for baseline assessment) using hai (hemagglutination inhibition assay) to the three influenza strains.

Eligibility criteria:
inclusion criteria: * male or female aged ≥ 60 years * healthy and/or medically stable with controlled chronic medical conditions (e.g. diabetes mellitus, hypertension ) able to help oneself exclusion criteria: * known history of systemic hypersensitivity to egg or chicken proteins or any of the vaccine components * influenza infection within the past 3 months * history of guillain barre syndrome (gbs) or brachial neuritis within 6 weeks of previous influenza vaccination * treatment with immunosuppressive or other immune-modifying drugs or cancer therapy within the past 6 months * any concomitant medication with aspirin * participation in other intervention study * incapacity to provide fully informed consent or be attentive to follow-up observations resulting from cognitive impairment, abuse of alcohol or drug addiction * random blood for dextrostix more than 200 mg/dl

Keywords: trivalent inactivated influenza vaccine
hiv and hcv intervention in drug treatment settings - 1

Conditions: Behavior Therapy

Summary: the purpose of this study is to test two strategies to reduce the risk of contracting human immunodeficiency virus (hiv) or hepatitis c virus (hcv) by reducing risk behaviors in patients undergoing drug detoxification.


Eligibility criteria:
volunteers will be iv drug users already enrolled in drug detoxification treatment.

Keywords: behavioral intervention
the alteration of macrophage function in the spleen tissues from patients with primary immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: this project was undertaken by qilu hospital of shandong university and other well-known hospitals in china. in order to report the alteration on the macrophage function in the spleen tissue of primary immune thrombocytopenia (itp).


Eligibility criteria:
inclusion criteria: * adult itp patients whose platelet counts remain less than 10 x 10\^9/l * patients whose platelet counts remain less than 30 x 10\^9/l and who continue to experience excessive bleeding after 4 to 6 weeks of appropriate medical treatment * patients who have experienced a transient response to primary treatment and have platelet counts less than 30 x 10\^9/l after 3 months * require continuous glucocorticoid therapy to maintain safe platelet counts * willing and able to sign written informed consent. exclusion criteria: * received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit. * current hiv infection or hepatitis b virus or hepatitis c virus infections. * severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) * female patients who are pregnant. * have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test. * patients who are deemed unsuitable for the study by the investigator.

Keywords: immune thrombocytopenia macrophage spleen tissue
hemithoracic arc radiotherapy post pleural decortication

Conditions: Malignant Pleural Mesothelioma

Summary: malignant pleural mesothelioma is an aggressive and refractory disease , the most aggressive treatment plan offered to these patients include trimodalitiy approach with chemotherapy as the mainstay of treatment . the rationale of post operative radiotherapy is to sterilize the post operative volume to reduce local failure meanwhile minimizing toxicities in this trial we are going to assess the safety and efficacy of radiotherapy in mesothelioma patients poat pleural decortication

this study will include malignant pleural mesothelioma patients treated by trimodalitiy approach starting with neoadjuvant chemotherapy followed by surgery in the form of pleural decortication then all patients will receive post operative hemithoracic radiation

Eligibility criteria:
inclusion criteria: * evidence of metastatic disease. * underwent pleural decortication. * able to provide informed consent. exclusion criteria: * poor pulmonary function tests. * recurrent or palliative cases. * inability to attend full course of radiotherapy or follow up visits.